Drug interactions
Betibeglogene autotemcel + Deferoxamine
Severity: Major
Betibeglogene autotemcel and Deferoxamine: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Some iron chelators can suppress bone marrow and may interfere with engraftment and hematologic recovery after gene therapy conditioning. Chelation around the time of myeloablation and infusion is therefore restricted.
What this interaction means in plain words
Betibeglogene autotemcel and Deferoxamine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Potential additive myelosuppressive or marrow-impairing effects of chelators could compromise engraftment; deferoxamine itself is less myelosuppressive than some chelators, so the mechanism is not firmly established.
What to do
Stop iron chelation at least 7 days before conditioning, and avoid myelosuppressive chelators for about 6 months after infusion. Use phlebotomy or a non-myelosuppressive chelator if iron reduction is needed.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Betibeglogene autotemcel and Deferoxamine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Deferoxamine
Frequently asked questions
Can I take Betibeglogene autotemcel with Deferoxamine?
MediHelp rates the interaction as major. Betibeglogene autotemcel and Deferoxamine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Some iron chelators can suppress bone marrow and may interfere with engraftment and hematologic recovery after gene therapy conditioning. Chelation around the time of myeloablation and infusion is therefore restricted.
How serious is the interaction between Betibeglogene autotemcel and Deferoxamine?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Stop iron chelation at least 7 days before conditioning, and avoid myelosuppressive chelators for about 6 months after infusion. Use phlebotomy or a non-myelosuppressive chelator if iron reduction is needed.
What other medicines interact with Deferoxamine?
MediHelp also lists interactions of Deferoxamine with, for example, Ascorbic acid, Exagamglogene autotemcel, Lovotibeglogene autotemcel. The full list is on the Deferoxamine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
